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at www.jvascsurg.org.INVITED COMMENTARYR. James Valentine, MD, Dallas, Texas
Experienced vascular surgeons recognize the value of topical
hemostatic agents to treat anastomotic bleeding. Regardless of
whether these agents actually contribute to local hemostasis or
merely allow time for full heparin reversal and activation of the
patient’s own clotting factors, we all use them. Numerous options
are currently available, and every surgeon has a favorite. However,
no agent has emerged as clearly superior in terms of rapid hemo-
stasis, ease of use, low cost, and minimal toxicity.
Enter cyanoacrylate, the holy grail of topical sealants. As
shown in the present study, this agent stops anastomotic bleeding
at the source, just like a self-sealing tire. By creating a mechanical
seal at leak sites, cyanoacrylate works independently of the patient’s
ability to form clot. Compared with the popular oxidized cellulose
alternative, cyanoacrylate achieves more rapid hemostasis at all
time intervals after clamp release. And it does this without any
measurable increase in complications.
Based on the elegant methods and statistical support of the
present study, the evidence for the superiority of cyanoacrylate
seems irrefutable. However, there are a number of problems with
the study design that should temper our enthusiasm beyond the
fact the agent is not currently on the market. The first issue is that
the study groups may not have been adequately matched. Signifi-
cantly more controls received aspirin, and more controls had takenulation effects of warfarin should have resolved within the 4 days of
discontinuation mandated by the inclusion criteria, we do not
know how many subjects were over-anticoagulated, and we have
no tests to ensure the absence of a residual anticoagulation effect.
A second concern is that the procedures were not standard-
ized. Expanded polytetrafluoroethylene grafts were not uniform,
and we do not know, for example, how many patients received
standard-wall vs thin-wall grafts. Intraoperative heparin dosing was
not standardized, nor was it monitored with the activated clotting
time. The use of protamine was left entirely up to the decision of
the surgeon, who was not blinded to the type of agent being used.
Although patients receiving cyanoacrylate had a mandatory 2-minute
wait time before clamps were removed, this was not the case for the
controls. A 2-minute exposure to microscopic amounts of bloodmay
have improved the hemostatic action of the control agent.
Despite these criticisms, there is much to commend this study.
It is prospective, randomized, and adequately powered. The results
are clear: to treat anastomotic bleeding, cyanoacrylate achieves
faster hemostasis than oxidized cellulose. Cyanoacrylate is easy to
apply and appears to have low toxicity. The present analysis is
certainly provocative, and the study agent is very promising; how-
ever, further experience with cyanoacrylate is needed before we can
say that it is superior to other agents.
